Screening/Prevention
Cyclophosphamide May Increase Cancer Risk Among Patients with Rheumatoid Arthritis
(03/10/2008)
A large study conducted in Canada reveals that patients who are treated for rheumatoid arthritis (RA) with the drug cyclophosphamide may have an increased risk for developing hematological cancers such as lymphoma.
Being Overweight Associated with Increased Risk of Several Cancers
(02/19/2008)
Excess bodyweight increases the risk of developing several types of cancer, according to results recently published in The Lancet.
Hepatitis C Virus May Increase Risk of Non-Hodgkin’s Lymphoma
(05/10/2007)
According to the results of a study published in the Journal of the American Medical Association, individuals who are infected with the hepatitis C virus are 20–30% more likely than non-infected individuals to develop non-Hodgkin’s lymphoma.
No Clear Link Between Allergy and Non-Hodgkin’s Lymphoma
(01/17/2007)
According to the results of studies conducted in Denmark, Sweden, and Finland, allergy does not appear to influence the risk of developing non-Hodgkin’s lymphoma. These results were published in the Journal of the National Cancer Institute.
Firefighters Face Increased Risk of Cancer
(11/15/2006)
According to the results of a study published in the Journal of Occupational and Environmental Medicine, firefighters have an increased risk of developing certain types of cancer.
More...
Indolent/Low Grade
Treanda® Included in NCCN Guidelines for CLL and NHL
(05/05/2008)
The chemotherapy agent Treanda® (bendamustine) has been added to the treatment guidelines of the National Comprehensive Cancer Network (NCCN) as an accepted treatment option for chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL).
Differences in IMRT Radiation Doses May Complicate Study Results in Lymphomas
(04/07/2008)
Differences between the prescribed dose of radiation in intensity modulated radiation therapy (IMRT) and the dose that’s actually delivered may make comparison studies in lymphomas difficult to interpret. These findings were reported in the Journal of the National Cancer Institute.
Statins May Reduce Effectiveness of Rituxan® in Non-Hodgkin’s Lymphoma
(04/01/2008)
Statins may reduce the effectiveness of Rituxan® (rituximab) in treatment of non-Hodgkin’s lymphoma (NHL), according to a recently published article in PLoS Med (the Public Library of Science journal).
Non-Hodgkin’s Lymphoma Survivors May Suffer Symptoms of Post Traumatic Stress
(02/26/2008)
Patients who have been diagnosed and treated for non-Hodgkin’s lymphoma may have symptoms of post traumatic stress disorder (PTSD). These finding were recently published in the Journal of Clinical Oncology.
Eliminating Infection at Diagnosis of Slow-growing NHL May Be Important Treatment Step
(02/22/2008)
Individuals with advanced non-Hodgkin’s lymphoma (NHL) who also have certain infections at diagnosis may be able to delay treatment for NHL if their infection is treated first. These results were recently published in the Annals of Oncology.
More...
Highly Aggressive/High Grade
Statins May Reduce Effectiveness of Rituxan® in Non-Hodgkin’s Lymphoma
(04/01/2008)
Statins may reduce the effectiveness of Rituxan® (rituximab) in treatment of non-Hodgkin’s lymphoma (NHL), according to a recently published article in PLoS Med (the Public Library of Science journal).
Non-Hodgkin’s Lymphoma Survivors May Suffer Symptoms of Post Traumatic Stress
(02/26/2008)
Patients who have been diagnosed and treated for non-Hodgkin’s lymphoma may have symptoms of post traumatic stress disorder (PTSD). These finding were recently published in the Journal of Clinical Oncology.
Tobacco and Alcohol May Decrease Survival for Non-Hodgkin’s Lymphoma Patients
(02/11/2008)
Heavy tobacco smoking and alcohol consumption may be associated with poor survival among patients with Non-Hodgkin’s Lymphoma (NHL). These findings were recently reported in the International Journal of Cancer.
Mozobil™ Increases Number of Stem Cells Available for Transplant
(08/01/2007)
According to the results of a Phase III clinical trial, treatment with the experimental drug Mozobil™ (plerixafor) increases the number of stem cells that can be collected from patients with non-Hodgkin’s lymphoma who are preparing for an autologous hematopoietic stem-cell transplant.
Long-term Quality-of-life Issues Persist Among Non-Hodgkin’s Lymphoma Survivors
(04/11/2007)
According to an article recently published in the journal Cancer, long-term survivors of non-Hodgkin’s lymphoma have quality-of-life concerns that deserve attention following treatment.
More...
Mantle Cell
Statins May Reduce Effectiveness of Rituxan® in Non-Hodgkin’s Lymphoma
(04/01/2008)
Statins may reduce the effectiveness of Rituxan® (rituximab) in treatment of non-Hodgkin’s lymphoma (NHL), according to a recently published article in PLoS Med (the Public Library of Science journal).
Non-Hodgkin’s Lymphoma Survivors May Suffer Symptoms of Post Traumatic Stress
(02/26/2008)
Patients who have been diagnosed and treated for non-Hodgkin’s lymphoma may have symptoms of post traumatic stress disorder (PTSD). These finding were recently published in the Journal of Clinical Oncology.
Long-term Quality-of-life Issues Persist Among Non-Hodgkin’s Lymphoma Survivors
(04/11/2007)
According to an article recently published in the journal Cancer, long-term survivors of non-Hodgkin’s lymphoma have quality-of-life concerns that deserve attention following treatment.
Velcade® Effective in Mantle Cell Lymphoma
(10/26/2006)
According to an article recently published in the Journal of Clinical Oncology, Velcade® (bortezomib) is an effective treatment option for patients with mantle cell lymphoma that has stopped responding to prior therapies.
Certain Variables Predict Risk of Secondary Leukemia After Stem Cell Transplant
(07/31/2006)
According to an article recently published in the Journal of Clinical Oncology, patients diagnosed with lymphoma who were previously treated with radiation therapy, those treated with four or more chemotherapy regimens, and those who take five days to collect enough stem cells for a transplant are at a higher risk of developing myelodysplastic syndromes or acute myeloid leukemia associated with a stem cell transplant.
More...
T-Cell
Statins May Reduce Effectiveness of Rituxan® in Non-Hodgkin’s Lymphoma
(04/01/2008)
Statins may reduce the effectiveness of Rituxan® (rituximab) in treatment of non-Hodgkin’s lymphoma (NHL), according to a recently published article in PLoS Med (the Public Library of Science journal).
Long-term Quality-of-life Issues Persist Among Non-Hodgkin’s Lymphoma Survivors
(04/11/2007)
According to an article recently published in the journal Cancer, long-term survivors of non-Hodgkin’s lymphoma have quality-of-life concerns that deserve attention following treatment.
Interleukin-12 Shows Promise Against Mycosis Fungoides
(10/30/2006)
According to the results of a phase II clinical trial published in the Journal of the American Academy of Dermatology, interleukin-12 (IL-12) produces a treatment response in some patients with previously treated mycosis fungoides, a type of T-cell lymphoma.
Zolinza™ Approved for Cutaneous T-cell Lymphoma
(10/10/2006)
The United States Food and Drug Administration (FDA) has approved Zolinza™ (vorinostat) for the treatment of patients with cutaneous (skin) T-cell lymphoma that has stopped responding to at least two previous systemic (full body) therapies.
Certain Variables Predict Risk of Secondary Leukemia After Stem Cell Transplant
(07/31/2006)
According to an article recently published in the Journal of Clinical Oncology, patients diagnosed with lymphoma who were previously treated with radiation therapy, those treated with four or more chemotherapy regimens, and those who take five days to collect enough stem cells for a transplant are at a higher risk of developing myelodysplastic syndromes or acute myeloid leukemia associated with a stem cell transplant.
More...
Recurrent
Statins May Reduce Effectiveness of Rituxan® in Non-Hodgkin’s Lymphoma
(04/01/2008)
Statins may reduce the effectiveness of Rituxan® (rituximab) in treatment of non-Hodgkin’s lymphoma (NHL), according to a recently published article in PLoS Med (the Public Library of Science journal).
Stem Cell Transplant May Improve Survival Among Elderly with Relapsed Non-Hodgkin’s Lymphoma
(03/11/2008)
A recent study reveals that elderly patients with relapsed non-Hodgkin’s Lymphoma (NHL) may benefit from autologous stem cell transplant. Results from the study, conducted at the M.D. Anderson Cancer Center in Texas, were recently published in Annals of Oncology.
Non-Hodgkin’s Lymphoma Survivors May Suffer Symptoms of Post Traumatic Stress
(02/26/2008)
Patients who have been diagnosed and treated for non-Hodgkin’s lymphoma may have symptoms of post traumatic stress disorder (PTSD). These finding were recently published in the Journal of Clinical Oncology.
Treanda™ Provides Lasting Responses in Recurrent Non-Hodgkin’s Lymphoma
(12/17/2007)
According to results recently presented at the 2007 annual meeting of the American Society of Hematology, the investigative agent Treanda™ (bendamustine) provides long-lasting responses in patients with non-Hodgkin’s lymphoma that has stopped responding to standard therapies.
Bexxar® in Stem Cell Transplants Effective in Non-Hodgkin’s Lymphoma
(12/06/2007)
According to an early online publication in the Journal of Clinical Oncology, Bexxar® (yttrium-90) used with high doses of chemotherapy followed by a stem cell transplant is safe and effective in the treatment of recurrent non-Hodgkin’s lymphoma.
More...
Aggressive/Intermediate Grade
Worse Prognosis for “Bulky” Disease Diffuse Large B-Cell Lymphoma
(05/08/2008)
Young patients with diffuse large-B-cell lymphoma (DLBCL) with cancerous masses that are 10.0 centimeters or greater in diameter are considered to have “bulky” disease and have a worse prognosis than those with smaller masses. These findings were published in Lancet Oncology.
Differences in IMRT Radiation Doses May Complicate Study Results in Lymphomas
(04/07/2008)
Differences between the prescribed dose of radiation in intensity modulated radiation therapy (IMRT) and the dose that’s actually delivered may make comparison studies in lymphomas difficult to interpret. These findings were reported in the Journal of the National Cancer Institute.
Statins May Reduce Effectiveness of Rituxan® in Non-Hodgkin’s Lymphoma
(04/01/2008)
Statins may reduce the effectiveness of Rituxan® (rituximab) in treatment of non-Hodgkin’s lymphoma (NHL), according to a recently published article in PLoS Med (the Public Library of Science journal).
Non-Hodgkin’s Lymphoma Survivors May Suffer Symptoms of Post Traumatic Stress
(02/26/2008)
Patients who have been diagnosed and treated for non-Hodgkin’s lymphoma may have symptoms of post traumatic stress disorder (PTSD). These finding were recently published in the Journal of Clinical Oncology.
Tobacco and Alcohol May Decrease Survival for Non-Hodgkin’s Lymphoma Patients
(02/11/2008)
Heavy tobacco smoking and alcohol consumption may be associated with poor survival among patients with Non-Hodgkin’s Lymphoma (NHL). These findings were recently reported in the International Journal of Cancer.
More...